TRENDS IN APPROVALS OF NEW DRUGS WITH ORPHAN DESIGNATION IN THE US (1983-2014)

Author(s)

Alhawwashi ST1, Alshahrani AM1, Alsahali SM1, Alasmari MS1, Seoane-Vazquez E2, Rodriguez-Monguio R3, Szeinbach SL4
1Massachusetts college of pharmacy and health science, Boston, MA, USA, 2MCPHS University, Boston, MA, USA, 3University of Massachusetts, Amherst, Amherst, MA, USA, 4The Ohio State University, Columbus, OH, USA

OBJECTIVES: Orphan drugs are indicated for rare diseases and conditions. We assessed trends in approvals of new drugs with orphan indications in the US and in the prevalence of orphan drugs approved by the FDA from 1983 to 2014 compared to non-orphan drug approvals in the same time frame METHODS: The study used regulatory and prevalence data derived from the US FDA, the European Medicines Agency (EMA), and other publicly available sources. Descriptive statistics and the chi-square test were performed in the study. RESULTS: A total of 103 BLAs and 799 NMEs were approved by the FDA from 1983 to 2014. The percentage of new drugs with orphan designation at approval was 43.7% for BLAs and 20.7% for NMEs (p<0.001).  Orphan drugs represented 13.9% of the new drugs approved from 1983 to 1989, 21.2% in the 1990s, 25.5% in the 2000s, and 33.8% from 2010 to 2014. Information about the prevalence of disease was available for 73.7% of the orphan drugs. Indications approved for use in diseases with a prevalence of less than 1000 patients (i.e.: ultra-orphan drugs) represented 8.4% of all new orphan drugs.  Ultra-orphan drugs represented 12.5%, 3.6%, 7.7%, and 15.8% of all orphan indications approved in the US from 1983-1989, 1990s, 2000s, and 2010-2014, respectively. CONCLUSIONS: This study found an increase in the percentage of drugs approved by the FDA for orphan diseases and conditions. Ultra orphan drugs revealed a greater increase over time than other orphan drugs as a proportion of all new drugs approved by the FDA. The limited innovation in diseases with large prevalence, the incentives provided by the Orphan Drug Act of 1982 and favorable reimbursement for orphan drugs in the US health care system may explain the increase in the approval of orphan drugs in the US.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PSY62

Topic

Health Policy & Regulatory

Topic Subcategory

Pricing Policy & Schemes

Disease

Rare and Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×